Synapse

← Expert Review of Precision Medicine and Drug Development

Papers in Expert Review of Precision Medicine and Drug Development

Page 1 · newest first

  1. Advances in functional radionuclide imaging and therapy for individualized management of patients: the growing importance of Nuclear Theranostics in Precision Oncology PracticeExpert Review of Precision Medicine and Drug Development · 2025
  2. Towards precision medicine for systemic lupus erythematosus and neuropsychiatric manifestationsExpert Review of Precision Medicine and Drug Development · 2025
  3. Immunotherapy for precision medicine in colorectal cancerExpert Review of Precision Medicine and Drug Development · 2025
  4. Challenges and opportunities for precision medicine in developing nationsExpert Review of Precision Medicine and Drug Development · 2025
  5. Drug discovery in the context of precision medicine and artificial intelligenceExpert Review of Precision Medicine and Drug Development · 2024
  6. Precision Medicine Paradigms in Allergic Rhinitis: Navigating Immunotherapy and Digital HealthcareExpert Review of Precision Medicine and Drug Development · 2024
  7. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinomaExpert Review of Precision Medicine and Drug Development · 2024
  8. Advances in the field of developing biomarkers for re-irradiation: a how-to guide to small, powerful data sets and artificial intelligenceExpert Review of Precision Medicine and Drug Development · 2024
  9. Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiationExpert Review of Precision Medicine and Drug Development · 2023
  10. Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approachesExpert Review of Precision Medicine and Drug Development · 2023
  11. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?Expert Review of Precision Medicine and Drug Development · 2022
  12. Accelerating precision ophthalmology: recent advancesExpert Review of Precision Medicine and Drug Development · 2022
  13. Personalizing treatments for patients based on cardiovascular phenotypingExpert Review of Precision Medicine and Drug Development · 2022
  14. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancerExpert Review of Precision Medicine and Drug Development · 2022
  15. Challenges in biomarker-based clinical trials for patients with gastrointestinal malignanciesExpert Review of Precision Medicine and Drug Development · 2022
  16. Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers – Where are we now?Expert Review of Precision Medicine and Drug Development · 2022
  17. Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directionsExpert Review of Precision Medicine and Drug Development · 2022
  18. Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug developmentExpert Review of Precision Medicine and Drug Development · 2022
  19. Personalised pharmacotherapy options for soft tissue sarcomasExpert Review of Precision Medicine and Drug Development · 2022
  20. Therapeutic potential of GABAA receptor subunit expression abnormalities in fragile X syndromeExpert Review of Precision Medicine and Drug Development · 2022
  21. Dopaminergic and other genes related to reward induced overeating, Bulimia, Anorexia Nervosa, and Binge eatingExpert Review of Precision Medicine and Drug Development · 2021
  22. Capabilities of neural network technologies for extracting new medical knowledge and enhancing precise decision making for patientsExpert Review of Precision Medicine and Drug Development · 2021
  23. Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimenExpert Review of Precision Medicine and Drug Development · 2021
  24. Prediction, diagnosis, prevention and treatment: genetic-led care of patients with diabetesExpert Review of Precision Medicine and Drug Development · 2021
  25. Targeted immunotherapies to consider for B Cell non-hodgkin lymphomaExpert Review of Precision Medicine and Drug Development · 2021
  26. Recent advances in precision medicine for the treatment of medullary thyroid cancerExpert Review of Precision Medicine and Drug Development · 2021
  27. Individualized management of cytomegalovirus in solid organ transplant recipientsExpert Review of Precision Medicine and Drug Development · 2021
  28. Brigatinib as a treatment of ALK-positive non-small cell lung cancerExpert Review of Precision Medicine and Drug Development · 2021
  29. Novel insights into the pathogenesis and treatment of NRAS mutant melanomaExpert Review of Precision Medicine and Drug Development · 2021
  30. An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromasExpert Review of Precision Medicine and Drug Development · 2021
  31. The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a reviewExpert Review of Precision Medicine and Drug Development · 2021
  32. Value of digital biomarkers in precision medicine: implications in cancer, autoimmune diseases, and COVID-19Expert Review of Precision Medicine and Drug Development · 2021
  33. The changing role of the pathologist in the era of targeted therapy in personalized medicineExpert Review of Precision Medicine and Drug Development · 2021
  34. Precision medicine for the treatment of triple negative breast cancer: opportunities and challengesExpert Review of Precision Medicine and Drug Development · 2021
  35. Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncologyExpert Review of Precision Medicine and Drug Development · 2021
  36. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?Expert Review of Precision Medicine and Drug Development · 2021
  37. Slotting metabolomics into routine precision medicineExpert Review of Precision Medicine and Drug Development · 2021
  38. Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancerExpert Review of Precision Medicine and Drug Development · 2021
  39. Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatmentExpert Review of Precision Medicine and Drug Development · 2021
  40. Future perspective: precision medicine to improve treatment results in the settings of allogenic stem cell transplantation for acute myelogenous leukemiaExpert Review of Precision Medicine and Drug Development · 2021
  41. Is there a worthwhile value in personalizing radiation therapy for breast cancer patients? Time for a new paradigm in the older adult populationExpert Review of Precision Medicine and Drug Development · 2021
  42. Mutation-dependent treatment approaches for patients with complex multiple myelomaExpert Review of Precision Medicine and Drug Development · 2021
  43. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancerExpert Review of Precision Medicine and Drug Development · 2021
  44. The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasisExpert Review of Precision Medicine and Drug Development · 2021
  45. Math, magnets, and medicine: enabling personalized oncologyExpert Review of Precision Medicine and Drug Development · 2021
  46. Global personalization of antibiotic therapy in critically ill patientsExpert Review of Precision Medicine and Drug Development · 2021
  47. Genetic analysis of primary renal cell carcinoma to determine treatment approachesExpert Review of Precision Medicine and Drug Development · 2021
  48. Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiencyExpert Review of Precision Medicine and Drug Development · 2020
  49. Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancerExpert Review of Precision Medicine and Drug Development · 2020
  50. Durvalumab for the treatment of PD-L1 non-small cell lung cancerExpert Review of Precision Medicine and Drug Development · 2020